Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | MLYCD | O95822 | 7/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549341 | 0.88 | PPARG (0.34) | PPARGPPARAAAK1 | |
| SCHEMBL2544478 | 0.85 | PPARG (0.36) | PPARGPPARAAKT1MLYCDAAK1 | |
| SCHEMBL2548965 | 0.84 | PPARG (0.37) | PPARGPPARAAKT1MLYCDAAK1 | |
| SCHEMBL2548962 | 0.84 | PPARG (0.37) | PPARGPPARAAKT1MLYCDAAK1 | |
| SCHEMBL2546511 | 0.82 | PPARG (0.35) | PPARGPPARAAKT1MLYCDAAK1 | |
| SCHEMBL2550430 | 0.81 | PPARG (0.34) | PPARGPPARATRPM8 | |
| SCHEMBL2550279 | 0.81 | PPARG (0.34) | PPARGPPARAAAK1TRPM8 | |
| SCHEMBL3704617 | 0.79 | ATM (0.39) | PPARGPPARAAKT1MLYCDAAK1 | |
| SCHEMBL3704620 | 0.79 | ATM (0.39) | PPARGPPARAAKT1MLYCDAAK1 | |
| SCHEMBL4303579 | 0.79 | PPARG (0.39) | PPARGPPARAAKT1AAK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | PPARG 232/4885PPARA 896/4885AKT1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.